250 Participants Needed

Contour Neurovascular System for Brain Aneurysm

(NECC Trial)

Recruiting at 20 trial locations
LE
RP
ER
CL
Overseen ByCarin Lindquist
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

The purpose of this trial is to gather data on the safety and effectiveness of the Contour /Contour 021 System in the treatment of wide-necked bifurcated saccular, intracranial aneurysms for submission to FDA in support of a premarket approval application for the device.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it does mention that if you are on anticoagulation medications (like warfarin) that cannot be stopped, you may not be eligible to participate.

Is the Contour Neurovascular System safe for treating brain aneurysms?

The Contour Neurovascular System has been reported as safe for treating intracranial aneurysms, with studies showing successful deployment and no procedure-related complications in patients.12345

How is the Contour Neurovascular System treatment different from other treatments for brain aneurysms?

The Contour Neurovascular System is unique because it treats brain aneurysms by disrupting blood flow within the aneurysm itself, rather than using traditional methods like coils or stents. This approach is particularly useful for wide-necked aneurysms, which are challenging to treat with other devices.12467

Research Team

Pascal M Jabbour MD | Jefferson Health

Pascal M Jabbour, MD

Principal Investigator

Jefferson University Hospitals

DL

Demetrius Lopes, MD

Principal Investigator

Advocate Medical Group - Brain and Spine Institute

Eligibility Criteria

This trial is for adults aged 18-75 with certain wide-necked brain aneurysms sized between 2 and 10.5 mm that require repair, who can follow the study schedule. Excluded are those on non-stop anticoagulants, with severe kidney issues not on dialysis, pregnant or breastfeeding women, participants in other conflicting studies, individuals allergic to device materials or contrast dye, and those with conditions affecting study compliance.

Inclusion Criteria

Patient or legally authorized representative has signed and dated an institutional review board (IRB)/Ethics Committee (EC)-approved written informed consent prior to initiation of any study procedures
If you have had a burst blood vessel in your brain, you must meet the guidelines from the American Heart Association and American Stroke Association for how it should be managed.
If you have an unruptured brain aneurysm, you need to meet the guidelines from the American Heart Association and American Stroke Association for managing this condition.
See 12 more

Exclusion Criteria

Target IA contains other devices/implants (e.g., coils) that could interfere with the correct placement of the Contour device
I have had symptoms or conditions that increase my risk of a stroke in the last 2 months.
I am on blood thinners that I cannot stop taking.
See 14 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the Contour NEurovasCular System™ for the treatment of wide-necked bifurcated saccular, intracranial aneurysms

30 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 year
Regular follow-up visits

Treatment Details

Interventions

  • Contour NEurovasCular System™
Trial Overview The Contour Neurovascular System™ is being tested for its safety and effectiveness in repairing wide-necked bifurcated saccular intracranial aneurysms. The data collected will support a premarket approval application to the FDA.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Attempted to TreatExperimental Treatment1 Intervention
Attempted to treat (ATT) with the investigational device

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cerus Endovascular, Inc.

Lead Sponsor

Trials
7
Recruited
600+

Cerus Endovascular, Ltd

Lead Sponsor

Trials
6
Recruited
350+

Findings from Research

The Contour Neurovascular System was successfully implanted in 90% of the 60 intracranial aneurysms treated, showing significant improvement in occlusion rates over time, reaching 89.3% at 1 year.
The device demonstrated a good safety profile with only 3.3% technical complications and no permanent morbidity or mortality, indicating it is a safe option for treating intracranial aneurysms.
Endosaccular flow disruption with the Contour Neurovascular System: angiographic and clinical results in a single-center study of 60 unruptured intracranial aneurysms.Biondi, A., Primikiris, P., Vitale, G., et al.[2023]

References

In vitro and in silico assessment of flow modulation after deploying the Contour Neurovascular System in intracranial aneurysm models. [2023]
Endosaccular flow disruption with the Contour Neurovascular System: angiographic and clinical results in a single-center study of 60 unruptured intracranial aneurysms. [2023]
Treatment of a middle cerebral artery bifurcation aneurysm with the novel Contour Neurovascular System compatible with 0.021″ catheters. [2022]
Comparison of the Contour Neurovascular System and Woven EndoBridge device for treatment of wide-necked cerebral aneurysms at a bifurcation or sidewall. [2023]
Patterns in neurosurgical adverse events: open cerebrovascular neurosurgery. [2022]
Endovascular treatment of wide-necked intracranial aneurysms using the novel Contour Neurovascular System: a single-center safety and feasibility study. [2020]
The Safety and Effectiveness of the Contour Neurovascular System (Contour) for the Treatment of Bifurcation Aneurysms: The CERUS Study. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security